Recruitment - Articles

“By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, research has found”. For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities.
A new Report from Visiongain. “By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, researcher has found”. For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities. This high-level management report examines the commercial prospects for anti-obesity prescription drugs in the global healthcare market. With obesity now the most common nutritional disorder…

The ins and outs of the daily life for Medical Sales Reps.
What does a Medical Representative Do? Click here to take a look at the Latest Medical Sales jobs. A medical representative is employed by a pharmaceutical company to maximise the prescribing of that pharmaceutical company's products in a geographical area. There are no strict formulae for how to maximise product prescribing - hard work is only part of the story and often working smarter is the key to success. This is why pharmaceutical companies are constantly looking for candidates who have the ability to think (and then put into practice) new ways of approaching sales opportunities. As an experienced representative you will know your territory, know your customers and have a clear idea which part of your territory offers the high…

Why do some people have allergies and some not? And why has the prevalence of allergic disorders been increasing over the past century, especially in industrialised, developed countries?
The hygiene hypothesis tries to explain why some people have allergies and some do not, and why the prevalence of allergic disorders has been increasing over the past century, especially in industrialised, developed countries. It suggests that the modern obsession with cleanliness may be counterproductive; in childhood, at least, resulting in the immune system becoming too sensitive to infection. Our reliance on antibacterial products with new born babies, has been linked to asthma and other allergic diseases. The Hygiene Hypothesis was first proposed by David P. Strachan in an article published in the BMJ…

Which current or future therapies will drive the sleep disorders market from 2008 to 2018? What is the patient identification rate for each of the therapeutic areas? What is the present state of the disease awareness? What R&D opportunities exist for ‘new comers’? Which key companies are involved in the market?
This report will tell you. The report focuses on the market for following sleep disorders: • Insomnia • Restless legs syndrome (RLS) • Narcolepsy and • Obstructive Sleep Apnoea / Hypopnea Syndrome (OSAHS) More than 80 sleep disorders have been identified. They affect over 200 million people worldwide. The market penetration for insomnia drugs has not reached saturation point. Opportunities remain. But with the introduction of several new products the market is set to see cha…

Forget sweat patches, VPLs and spots…a new survey commissioned by Kleenex® has found that it’s blowing your nose in public that causes us the most embarrassment! The survey of hay fever sufferers reveals that most people prefer a quiet sniff over a good nose blow when out and about. However, allergy specialists warn that the more discreet option actually makes symptoms worse.
A nationwide survey of over 2000 people found that a quarter of hay fever sufferers felt they were unable to blow their nose properly when in public. However, Dr Adrian Morris, a specialist in allergy and respiratory medicine at London’s Royal Brompton Hospital, explains “the only way to remove the irritant is by blowing into a tissue, thereby expelling the substance from your body.” Over half of respondents to the Kl…

Asthma is a significant health problem. Acording to the National Asthma Campaign, the condition continues to grow, and in the UK an estimated 8 million people are diagnosed as having asthma, with 5 million people receiving treatment. The cost of asthma to the NHS is more than £850 million a year.
Asthma is a condition that affects the airways – the small tubes that carry air in and out of the lungs. When a person with asthma comes into contact with an asthma trigger, the muscle around the walls of the airways tightens so that the airway becomes narrower. The lining of the airways becomes inflamed and starts to swell. Often sticky mucus or phlegm is produced. All these reactions cause the airways to become narrower and irritated – leading to the symptoms of asthma. How do you get it? Asthm…

Bell Pottinger Group has formed Bell Pottinger Health, a new business dedicated to leading the expansion of its health franchise with Shipra Singh newly hired as Managing Director. Simultaneously the company has brought in a life science investor relations team led by Mike Wort.
Bell Pottinger Group has formed Bell Pottinger Health, a new business dedicated to leading the expansion of its health franchise with Shipra Singh newly hired as Managing Director. Simultaneously the company has brought in a life science investor relations team led by Mike Wort. Bell Pottinger Health, which will report to Kevin Murray, Chairman of Bell Pottinger Group, will be led by De Facto Communications CEO Richard Anderson in the role of Chairman and by Shipra Singh, formerly of Hill & Knowlton, as Managi…

Research led by the University of Warwick has uncovered exactly how the bacterium Streptococcus pneumoniae has become resistant to the antibiotic penicillin. The same research could also open up MRSA to attack by penicillin and help create a library of designer antibiotics to use against a range of other dangerous bacteria.
According to Dr Adrian Lloyd of the University of Warwick (UK) "We have reconsitiuted and biochemically characterised one of the steps essential to clinical resistance to penicillin in Streptococcus pneumoniae. Our data are likely to be extremely useful in the design of inhibitors of this step that will restore penicillin sensitivity to Streptococcal infections that have become resistant to this antibiotic. Because this step is conserved in other pathogens, there is…

Roche to announce new breast cancer data pointing to better survival chances and potential for cure Phase II results suggest Avastin can be used in curative setting
Basel, 10th December 2007 – Experts attending the 30th San Antonio Breast Cancer Symposium (SABCS) December 13-16, will be amongst the first to hear new data that highlight further advances in the treatment of breast cancer with Avastin, Herceptin, pertuzumab and Xeloda. Data to be presented will show that Avastin may have the potential to be used as a curative treatment following breast cancer surgery. Results from the randomized CHAT study (Xeloda, Herceptin and Taxotere), will show that Xeloda when added to Herceptin and docetaxel offers important survival benefits for women with advanced breast cancer. In addition, data…

Spanish pharmaceutical company Almirall has unveiled a state-of-the-art new dry-powder inhaler in which it plans to market its lead pipeline compound aclidinium bromide for chronic obstructive pulmonary disease (COPD). The device, developed by specialist inhaler company Sofotec, acquired by Almirall in 2006, is set to become the gold standard in inhaler design, claims the company, and will aid patient compliance with anticholinergic medication.
Spanish pharmaceutical company Almirall has unveiled a state-of-the-art new dry-powder inhaler in which it plans to market its lead pipeline compound aclidinium bromide for chronic obstructive pulmonary disease (COPD). The device, developed by specialist inhaler company Sofotec, acquired by Almirall in 2006, is set to become the gold standard in inha…

Are you keen to join a young, entrepreneurial, fast growth organisation? We'd like to hear from you.
PharmiWeb Solutions - publisher of PharmiWeb.com - is one of the UK's leading providers of web based solutions to the pharmaceutical sector. In fact we're so good that we this year we have been shortlisted for the UK AOP Best Business Online Publisher 2007 Award. And we're expanding too. This is where you come in. We are looking for a Digital Account/Project Manager, to manage the implementation of innovative web and software developments for our blue chip customer base. Are you keen to join a young, entrepreneurial, fast growth organisation? We'd like to hear from you. You’ll be a good all rounder, equally at home with a web design and build project as you are with managing online adve…

PharmiWeb Solutions’ Managing Director Paul Hartigan was a speaker at the annual conference of the Pharmaceutical Marketing Society in London yesterday, November 26th, hosted by the Royal College of Nurses. He reviews his thoughts on the day here.
The theme of the event was Return on Investment in pharma marketing, with one of the key strands being ROI for emarketing. Having been to a number of conferences on this topic over the past few years, there has been an evident sea change in the general sentiment of the delegates from uncertainty and disbelief three or four years ago, to cautious optimism last year, through to a general feeling of enthusiasm at this particular event. Admittedly, this is a self-selecting audience – it’s unlikely anyone would attend without at least a passing intere…

PharmiWeb Solutions are looking for a Client Project Manager, to manage the implementation of innovative web and software developments for our blue chip customer base.
PharmiWeb Solutions - publisher of PharmiWeb.com - is one of the UK's leading providers of web based solutions to the pharmaceutical sector. In fact we're so good that we this year we have been shortlisted for the UK AOP Best Business Online Publisher 2007 Award. And we're expanding too. This is where you come in. We are looking for a Client Project Manager, to manage the implementation of innovative web and software developments for our blue chip customer base. If you are keen to join a young, entrepreneurial, fast growth organisation, we'd like to hear from you. You'll need a blend of web, pharma, marketing and project…

Two things; firstly among all of the great business concepts of the last few decades the franchise model has always surfaced to the very top. Secondly, over the next decade the introduction of hundreds of fresh, locally nurtured franchise concepts emerging within Dubai and the Gulf States will set the stage for a great revolution of nouvo-consumerism. So what are the four key factors driving this movement?
Firstly, the places to park new concepts; the current, ever-expanding construction phases in Dubai, UAE, GCC and all over Asia, provide a highly fertile ground for such concepts to nestle in, a home in the newly designed and creatively appointed decors, so that the cute new concepts with the most lavish and appealing ideas would flourish. The combination of creative concepts blended w…

Healthcare specialist online publisher and e-business services provider PharmiWeb Solutions has been shortlisted for the Best Online Publisher awards by the UK Association of Online Publishers (AOP). Paul Hartigan, PharmiWeb CEO, commented on the news, which was announced this week, “We’re delighted to be shortlisted for such a prestigious award.
Healthcare specialist online publisher and e-business services provider PharmiWeb Solutions has been shortlisted for the Best Online Publisher awards by the UK Association of Online Publishers (AOP). Paul Hartigan, PharmiWeb CEO, commented on the news, which was announced this week, “We’re delighted to be shortlisted for such a prestigious award. We enjoy punching above our weight, and relish the fact that we are up against major international p…

BIPOLAR DISORDER: a new holistic approach to controlling mood disturbance from multiple aspects could revolutionise patients’ prospects
BIPOLAR DISORDER: a new holistic approach to controlling mood disturbance from multiple aspects could revolutionise patients’ prospects Treatment of mood disturbance in bipolar disorder is undergoing a paradigm shift. Traditionally, drug therapy has been focussed on efficacy in acute mania or depression. Now psychiatrists are realising the need to evaluate drug treatments from other perspectives, Their full effects as acute and mood-stabilising agents, side effect profiles, effects on neurocognitive functioning, quality of life, and on psychosocial functioning, are also important when considering therapy. Bipolar disorder, the condition where mood swings…

Barrington James Limited currently places candidates extensively throughout the UK and Europe in many areas such as Clinical Research, Regulatory Affairs, Medical Affairs, Data Management and Business Development. Working with key Barrington James Team Leaders such as Paul Duffy, Tony Kelleher will be charged with growing the team to assist with their Client’s needs throughout Europe. Dan Barrington, Director, said “…we are delighted Tony agreed to join Barrington James Limited, he brings
Market Leading Pharmaceutical Recruitment Consultancy Barrington James Limited is happy to announce the appointment of Tony Kelleher as its Sales Manager. Tony has 20+ years of Recruitment Experience and joins with the brief to assist with Barrington James’ ambitious growth plans across the UK and Europe.…

The anti-EGFR targeting cancer therapy Erbitux (cetuximab), has been approved in Europe for the treatment of locally advanced head and neck cancer in conjunction with radiotherapy and as a third-line treatment in combination with irinotecan-based chemotherapy for patients with metastatic colorectal cancer. New data from the phase III EXTREME and CRYSTAL trials, presented at the American Society of Clinical Oncology’s annual meeting, show cetuximab added to chemotherapy is also an effective first
The anti-EGFR targeting cancer therapy Erbitux (cetuximab), has been approved in Europe for the treatment of locally advanced head and neck cancer in conjunction with radiotherapy and as a third-line treatment in combination with irinotecan-based chemotherapy for patients with metastatic colorectal…

Those of you who know our CEO Paul Hartigan will realise that he is a keen cyclist (we have to repeatedly ask him not to turn up to customer meetings in some of his garishly coloured Lycra).
But this time, is he going too far? On June 28th, Paul will set off from Hampton Court, London, on a 3 day, 600km stage race from London to Paris (the L2P). Other riders will include top 1980s pro cyclist Sean Kelly, and European Classics star, Johann Museuw. This will ensure a pace designed to make the lesser rider suffer. So why bother? Well, the ride is designed as a sponsorship event to benefit three Children’s charities This year L2P will be supporting three charities: Morning Star Children’s Centre, a day care facility for babies and young children, often orphans, who are infected with HIV/AI…

Results of the CRYSTAL trial investigating first-line cetuximab therapy in addition to irinotecan-based therapy in metastatic colorectal cancer (mCRC) were presented by the study’s lead investigator, Professor Eric Van Cutsem of University Hospital, Gasthuisberg, Leuven, Belgium.
The anti-EGFR targeting cancer therapy Erbitux (cetuximab), has been approved in Europe for the treatment of locally advanced head and neck cancer in conjunction with radiotherapy and as a third-line treatment in combination with irinotecan-based chemotherapy for patients with metastatic colorectal cancer. New data from the phase III EXTREME and CRYSTAL trials, presented at the American Society of Clinical Oncology’s annual meeting, show cetuximab added to chemotherapy is also an effective first-line therapy for b…